No products in the cart.
Rabbit Polyclonal Phospho-BRCA1 (S1423) antibody (STJ90198)
Supplier: St John’s Laboratory Ltd.
Recommended applications: WB, IHC, ELISA
Recommended dilution: WB 1:500-1:2000; IHC 1:100-1:300; ELISA 1:5000;
Recommended protocols: check protocols
Click or hover above images to see image description for BRCA1 (phospho Ser1423) Polyclonal Antibody.
Check alternative names for the antibodyExpand
BRCA1 antibody, RNF53 antibody,|BRCA 1 antibody|BRCA1 antibody|BRCA1/BRCA2 containing complex subunit 1 antibody|BRCA1/BRCA2-containing complex, subunit 1 antibody|BRCA1_HUMAN antibody|BRCAI antibody|BRCC 1 antibody|BRCC1 antibody|Breast and ovarian cancer susceptibility protein 1 antibody|Breast Cancer 1 antibody|Breast Cancer 1 Early Onset antibody|Breast cancer type 1 susceptibility protein antibody|BROVCA1 antibody|IRIS antibody|PNCA4 antibody|PPP1R53 antibody|Protein phosphatase 1 regulatory subunit 53 antibody|PSCP antibody|RING finger protein 53 antibody|RNF53 antibody|Anti-BRCA1 antibody [MS110] (ab16780)
SCBT cat No: sc-135732|sc-514797|sc-642|sc-641|sc-6954|sc-514640|sc-56030|sc-7867|sc-28234|sc-646|sc-1021|sc-1553|sc-293185|sc-1817|sc-28235|sc-8326|
BRCA1 (phospho Ser1423) Polyclonal Antibody
|Catalogue No.|| |
Phospho-BRCA1 (S1423) Polyclonal Antibody detects endogenous levels of BRCA1 protein only when phosphorylated at S1423.
Synthesized phospho-peptide derived from BRCA1 (phospho Ser1423) at AA range 1360-1440
WB, IHC, ELISA
|Recommended dilution|| |
WB 1:500-1:2000; IHC 1:100-1:300; ELISA 1:5000;
|Molecular weight|| |
BRCA1 (phospho Ser1423) Antibody was tube-contained. Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
BRCA1 (phospho Ser1423) Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
-20 Celsius degree. Avoid repeated freeze/thaw cycles.
|Alternative antibody names|| |
Breast cancer type 1 susceptibility protein antibody, RING finger protein 53 antibody
|Protein names|| |
Breast cancer type 1 susceptibility protein , RING finger protein 53
|Protein function|| |
E3 ubiquitin-protein ligase that specifically mediates the formation of ‘Lys-6’-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage. It is unclear whether it also mediates the formation of other types of polyubiquitin chains. The E3 ubiquitin-protein ligase activity is required for its tumor suppressor function. The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Regulates centrosomal microtubule nucleation. Required for normal cell cycle progression from G2 to mitosis. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Involved in transcriptional regulation of P21 in response to DNA damage. Required for FANCD2 targeting to sites of DNA damage. May function as a transcriptional regulator. Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation. Contributes to homologous recombination repair (HRR) via its direct interaction with PALB2, fine-tunes recombinational repair partly through its modulatory role in the PALB2-dependent loading of BRCA2-RAD51 repair machinery at DNA breaks. Component of the BRCA1-RBBP8 complex which regulates CHEK1 activation and controls cell cycle G2/M checkpoints on DNA damage via BRCA1-mediated ubiquitination of RBBP8. Acts as a transcriptional activator . / The E3 ubiquitin-protein ligase activity is inhibited by phosphorylation by AURKA. Activity is increased by phosphatase treatment. /
|Protein tissue specificity|| |
Isoform 1 and isoform 3 are widely expressed. Isoform 3 is reduced or absent in several breast and ovarian cancer cell lines.
|Involvement in disease|| |
Breast cancer (BC) [MIM:114480]: A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case. . Note: Disease susceptibility is associated with variations affecting the gene represented in this entry. Mutations in BRCA1 are thought to be responsible for 45% of inherited breast cancer. Moreover, BRCA1 carriers have a 4-fold increased risk of colon cancer, whereas male carriers face a 3-fold increased risk of prostate cancer. Cells lacking BRCA1 show defects in DNA repair by homologous recombination.; Breast-ovarian cancer, familial, 1 (BROVCA1) [MIM:604370]: A condition associated with familial predisposition to cancer of the breast and ovaries. Characteristic features in affected families are an early age of onset of breast cancer (often before age 50), increased chance of bilateral cancers (cancer that develop in both breasts, or both ovaries, independently), frequent occurrence of breast cancer among men, increased incidence of tumors of other specific organs, such as the prostate. . Note: Disease susceptibility is associated with variations affecting the gene represented in this entry. Mutations in BRCA1 are thought to be responsible for more than 80% of inherited breast-ovarian cancer.; Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. . Note: Disease susceptibility is associated with variations affecting the gene represented in this entry.; Pancreatic cancer 4 (PNCA4) [MIM:614320]: A malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue. . Note: Disease susceptibility is associated with variations affecting the gene represented in this entry.
|Protein sequence and domain|| |
The BRCT domains recognize and bind phosphorylated pSXXF motif on proteins. The interaction with the phosphorylated pSXXF motif of FAM175A/Abraxas, recruits BRCA1 at DNA damage sites. / The RING-type zinc finger domain interacts with BAP1. / Contains 2 BRCT domains. / Contains 1 RING-type zinc finger.
|Protein post-translational modifications|| |
Phosphorylation at Ser-308 by AURKA is required for normal cell cycle progression from G2 to mitosis. Phosphorylated in response to IR, UV, and various stimuli that cause checkpoint activation, probably by ATM or ATR. Phosphorylation at Ser-988 by CHEK2 regulates mitotic spindle assembly. / Autoubiquitinated, undergoes ‘Lys-6’-linked polyubiquitination. ‘Lys-6’-linked polyubiquitination does not promote degradation.
|Protein cellular localization|| |
Nucleus / Chromosome / Cytoplasm / Cytoplasm / Cytoplasm
AntibodyPlus can customize BRCA1 (phospho Ser1423) Antibody according to your requirement, including bulk product size,etc. Please contact firstname.lastname@example.org. AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.
St John’s Laboratory Ltd.
|Product type|| |
There are no reviews for this product yet.
By submitting a review, get following benefits:
1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!
There is no extra validation for this product yet.
Check other extra validated antibodies below: